We narrowed to 1,077 results for: aav

#112000-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-GCaMP6f (#112000). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6f plasmid DNA. Synapsin-driven, axon-targeted GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

March 12, 2021

Academic Institutions and Nonprofits only

#50476-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#50467-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 10, 2019

Academic Institutions and Nonprofits only

#62723-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] (#62723). In addition to the viral particles, you will also receive purified pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] plasmid DNA. Cre-dependent expression of ChrimsonR-tdTomato under the control of the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#135630-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-dTom-nlsdTom (#135630). In addition to the viral particles, you will also receive purified pAAV-S5E2-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Jan. 6, 2022

Academic Institutions and Nonprofits only

#83896-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only

#100896-AAV5

Ready-to-use AAV5 particles produced from pAAV.GFA104.PI.eGFP.WPRE.bGH (#100896). In addition to the viral particles, you will also receive purified pAAV.GFA104.PI.eGFP.WPRE.bGH plasmid DNA. GFA104-driven eGFP expression. These AAV preparations are suitable purity for injection into animals.

Philip Haydon

Ortinski et al Nat Neurosci. 2010 May;13(5):584-91. doi

April 6, 2018

Academic Institutions and Nonprofits only

#84446-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

June 26, 2024

Academic Institutions and Nonprofits only

#164510-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 (#164510). In addition to the viral particles, you will also receive purified pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 plasmid DNA. Synapsin-driven, cytosolic-targeted iGlucoSnFR-mRuby2

Loren Looger

Keller et al Cell Rep. 2021 Jun 22;35(12):109284. doi

Nov. 29, 2021

Academic Institutions and Nonprofits only

#137125-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-sRGECO (#137125). In addition to the viral particles, you will also receive purified pAAV-Ef1a-sRGECO plasmid DNA. EF1a-driven expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#106192-AAV1

Ready-to-use AAV1 particles produced from pAAV.GFAP.SF-iGluSnFR.A184S (#106192). In addition to the viral particles, you will also receive purified pAAV.GFAP.SF-iGluSnFR.A184S plasmid DNA. GFAP-driven expression of SF-iGluSnFR.A184S. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Sept. 11, 2020

Academic Institutions and Nonprofits only

#99121-AAV1

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-DIO-tTA (#99121). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-DIO-tTA plasmid DNA. Cre-dependent expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

April 4, 2019

Academic Institutions and Nonprofits only

#106176-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.S72A (#106176). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.S72A plasmid DNA. hSynapsin driven SF-iGluSnFR.S72A, glutamate sensor. The S72A mutant has lower affinity for glutamate. Slower on-rate and faster off-rate. Enhanced temporal resolution and spatial resolution. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 25, 2019

Academic Institutions and Nonprofits only

#58376-AAV8

Ready-to-use AAV8 particles produced from pAAV/D377Y-mPCSK9 (#58376). In addition to the viral particles, you will also receive purified pAAV/D377Y-mPCSK9 plasmid DNA. hAAT-driven expression of mutant (D377Y) murine PCSK9. These AAV preparations are suitable purity for injection into animals.

Jacob Bentzon

Bjorklund et al Circ Res. 2014 May 23;114(11):1684-9. do

July 30, 2025

Academic Institutions and Nonprofits only

#50467-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2020

Academic Institutions and Nonprofits only

#20949-AAV9

Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 12, 2018

Academic Institutions and Nonprofits only

#100857-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.NES-jRGECO1b.WPRE.SV40 (#100857). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRGECO1b.WPRE.SV40 plasmid DNA. Syn-driven jRGECO1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 18, 2018

Academic Institutions and Nonprofits only

#105677-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Oct. 21, 2024

Academic Institutions and Nonprofits only

#178329-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only